



February 11th 2021

The Honorable Senator Sanborn Senate Chair, Representative Tepler House Chair
Members, Joint Standing Committee on Health Coverage, Insurance and Financial Services
Cross Building, Room 220
Augusta, ME 04330

RE: LD 172 An Act To Improve Prescription Information Access

Dear Chair Sanborn, Chair Tepler, Members of the Committee:

On behalf of the Pharmaceutical Care Management Association (PCMA), I am writing to you to oppose LD 172, An Act To Improve Prescription Information Access. PCMA is the national trade association representing pharmacy benefit managers (PBMs), which manage prescription drug benefits for large employers, health insurance carriers, labor trusts, government programs, and other payers.

We appreciate the opportunity to provide public comment on LD 172 which would require a scannable barcode that is used to direct a patient to additional information on the prescription bottle. A concern we have is related to the limited real estate that is currently on the prescription bottle. Any additional elements, such as a barcode, that would need to be added to a bottle would sacrifice critical information that is currently required to be on a label.

Additionally, we are concerned that the language appears to be specific to one product. PCMA's member companies have a variety of different products in the marketplace that provide prescription label information to individuals who are visually impaired. We would request that the language be expanded to include the other products available in the marketplace.

It is for these reasons that we remain concerned the language outlined in LD 172. Thank you for the opportunity to provide our feedback on the issues above. Please contact me at shallemeier@pcmanet.org if you have any questions.

Sincerely,

A handwritten signature in black ink, appearing to read "Sam Hallemeier".

Sam Hallemeier
Director, State Affairs